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Abstract
Background: The survival time in nursing homes (NHs) in Alzheimer’s disease (AD) might be affected by
sociodemographic/clinical characteristics, rate of disease progression, and use of specific medications and
community-based services. Whether different aspects of cholinesterase inhibitor (ChEI) therapy modify time
spent in NHs is unclear. Therefore, we examined the relationship between these potential predictors and
survival time in NHs.
Methods: This prospective, multicenter study of ChEI treatment in clinical practice included 220 deceased patients
clinically diagnosed with mild-to-moderate AD who were admitted to NHs during the study. Cognitive and
activities of daily living (ADL) performance, ChEI dose, and amount of services used/week were evaluated
every 6 months over 3 years. Dates of nursing-home placement (NHP) and death were recorded. Variables
that determined survival time in NHs were analyzed using general linear models.
Results: The mean survival time in NHs was 4.06 years (men, 2.78 years; women, 4.53 years; P < 0.001). The
multivariate model showed that a shorter stay in NHs was associated with the interaction term male living
with a family member, use of antihypertensive/cardiac therapy or anxiolytics/sedatives/hypnotics, and worse
basic ADL at NHP, but not with age or cognitive and instrumental ADL capacities.
Conclusions: Increased community-based care did not reduce the survival time in NHs among individuals with AD.
Men living with family spent significantly less time in NHs compared with the corresponding women, which
suggests that the situation of female spouses of AD patients may need attention and possibly support. There was
no indication that different aspects of ChEI therapy, e.g., drug type, dose, or duration, alter survival time in NHs.
Keywords: Alzheimer’s disease, Cholinesterase inhibitors, Activities of daily living, Cognition, Community-based
services, Survival time in nursing homes, Sex, Predictors, Longitudinal study
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Background
Alzheimer’s disease (AD) is a progressive, neurodegene-
rative disorder that initially exhibits cognitive symptoms,
such as impaired memory, disorientation, and reduced
executive ability, which are accompanied by deterioration
in activities of daily living (ADL) [1]. AD is the most com-
mon form of dementia and its prevalence increases expo-
nentially with age. About 10 % of people over 65 years will
experience some type of dementia, whereas one-third of
those over 85 will be affected by this condition [2].
The need of assistance starts early in patients with AD,
and deficits in instrumental ADL tasks have been reported
even in the stages of mild cognitive impairment and mild
AD [3, 4]. Their care needs develop constantly and about
half of the individuals with dementia need help with per-
sonal care, whereas the remaining half will need such help
over time [5]. This results in an increasing demand for
community-based services (e.g., home help and adult day
care) and nursing-home placement (NHP), the costs of
which rise dramatically with advancing disease severity
[6]. Currently, about 30 %–50 % of people with dementia
in high-income countries receive care in nursing homes
(NHs) [5]. The annual cost of NH care in Sweden for one
recipient in 2014 was SEK 610,000 (~USD 69,600, ~EUR
63,700) [7]. In middle-income countries in particular, an
increased demand for high-quality care is expected. It is
necessary for health authorities to plan and allocate re-
sources for different types of dementia care and special
accommodation [5].
The symptomatic treatment mainly recommended for
mild-to-moderate AD is cholinesterase inhibitor (ChEI;
donepezil, rivastigmine, and galantamine) therapy. ChEIs
inhibit the degradation of the neurotransmitter acetylcho-
line by acetylcholinesterase, resulting in increased levels
of acetylcholine in the synaptic cleft and increased avai-
lability for receptor absorption. This sustains cholinergic
transmission and improves communication between neu-
rons [8]. The level of short-term response to ChEI and the
long-term outcomes vary among persons with AD [9]. No
difference in effect has been detected among the three
ChEI agents [10, 11]. However, higher ChEI doses, regard-
less of drug agent, were associated with better longitudinal
cognitive and functional capacities [11–13]. Significant
associations between a higher dose of ChEI and lower
amount of home-help services [14], postponed need for
NHP [15, 16], and longer life-span [17] have also been
observed. Moreover, we reported recently that a longer
ChEI treatment duration was independently related to
longer survival in AD [17]. Whether different aspects of
ChEI therapy alter the survival time in NHs has not been
investigated.
Few previous studies have described the length of time
spent in NHs for AD patients exclusively. Two American
studies observed a median of 33 and 38.57 months, re-
spectively [18, 19], although the factors that might affect
this parameter were not addressed. However, predictors of
mortality in NH residents with AD have been reported,
such as male sex, older age, and functional disability. The
severity of dementia and the impact of comorbid illnesses
yielded inconsistent results [20].
Here, we aimed to identify sociodemographic and clinical
factors, including various aspects of ChEI treatment, AD
progression, and use of community-based services, that
might predict survival time in NHs.
Methods
Participants and setting
The Swedish Alzheimer Treatment Study (SATS) began in
1997 to investigate different aspects of the effectiveness of
long-term ChEI therapy in a routine clinical setting. SATS
is a 3-year, open-label, observational, nonrandomized,
multicenter study that was described previously [4, 11, 13,
14, 16, 17]. Before inclusion, all patients underwent a tho-
rough clinical investigation including medical history,
physical and neurological examinations, cognitive evalua-
tions, laboratory tests, and cerebral computed tomography
to rule out other causes of dementia. Additionally, in some
centers, the individuals were investigated further through
cerebrospinal fluid tap, measurement of regional cerebral
blood flow (Cortexplorer using 133-Xenon inhalation or
single-photon emission computed tomography), electro-
encephalography, and neuropsychological tests. Outpa-
tients aged ≥40 years who had been clinically diagnosed
with dementia, as defined by the Diagnostic and Statistical
Manual of Mental Disorders, 4th edition (DSM-IV) [21],
and with possible or probable AD according to the criteria
of the National Institute of Neurological and Communica-
tive Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association (NINCDS-ADRDA) [22]
were considered for inclusion in the SATS. The parti-
cipants were diagnosed by specialists in dementia disor-
ders. Moreover, the individuals had to be living at their
own home at the time of AD diagnosis, have a responsible
caregiver, and be assessable using the Mini-Mental State
Examination (MMSE) [23] at the start of ChEI treatment
(baseline). The 1,258 participants enrolled here were
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prospectively recruited from 14 memory clinics across
Sweden; most of them were in the mild-to-moderate stages
of AD. All 220 deceased individuals who were admitted to
NHs during the SATS and had MMSE baseline scores from
10 to 26 were included in this study.
The patients were evaluated in a structured follow-up
program, which assessed cognition, instrumental and
basic ADL performance, and community-based service
utilization (home-help services and adult day care) be-
fore the start of ChEI therapy and semi-annually over
3 years. After inclusion and baseline evaluations, the
participants were prescribed ChEIs according to the
approved product recommendations. The choice of drug
and dosage for each individual was left entirely up to the
dementia specialist’s discretion and professional judgment,
i.e., the standard routine in clinical practice. The ChEI
dose was recorded after 2 months of treatment, and every
6 months after the baseline. Trained dementia nurses ob-
tained the ADL assessment and the amount of service
used/week (if any) from an interview with the caregiver
(usually the spouse or an adult child). Medications other
than ChEIs were permitted, with the exception of meman-
tine, and were documented at baseline. If memantine was
initiated, the patient dropped out from the SATS at that
time point.
The dementia specialist obtained the estimated age at
the onset of AD from an interview with the caregiver.
The date of NHP was obtained from medical records,
and NHP was defined as the permanent entry to a
licensed skilled-nursing facility with 24 h care; i.e., the
residents were not discharged home, and rehabilitative
or respite care was excluded. If hospitalization occurred
before NHP, the date of hospital admission was used.
The date of death (up until December 31, 2014) was
obtained from the Swedish population register (Swedish
Tax Agency).
Assessment scales
Cognitive ability was evaluated using the MMSE scale
(0–30 points), in which a lower score indicates more
impaired cognition, and the Alzheimer’s Disease Assess-
ment Scale—cognitive subscale (ADAS-cog) (0–70 points)
[24], in which a lower score indicates better cognitive sta-
tus. Functional capacity was assessed using the Instrumen-
tal Activities of Daily Living (IADL) scale [25], comprising
eight items: telephone use, shopping, food preparation,
housekeeping, doing laundry, mode of transportation,
responsibility for own medications, and ability to handle
finances. Each item was scored from 1 (no impairment) to
3–5 (severe impairment), allowing a total range of 8–31
points. Basic ADL were measured using the Physical
Self-Maintenance Scale (PSMS) [25], comprising six items:
toilet use, feeding, dressing, grooming, physical ambulation,
and bathing. Each item was scored from 1 (no impairment)
to 5 (severe impairment), giving a total range of 6–30 points.
Statistical analyses
The IBM Statistical Package for the Social Sciences (SPSS)
for Windows (version 22.0; IBM Corporation, Armonk,
NY, USA) was used to perform statistical analyses. The
level of significance was defined as P < 0.05 if not other-
wise specified, and all tests were two-tailed. Parametric
tests were used because of the large sample size and the
approximately normally distributed continuous variables.
A one-way analysis of variance (ANOVA) was performed
to compare the differences between the means obtained
for three or more independent groups, such as the inter-
action effect of sex by living status, and groups divided
according to PSMS score. A t test was used to analyze two
independent groups, e.g., sex, living status, and use of
specific medications. Pearson’s correlation coefficient was
calculated to investigate any linear associations between
continuous predictors, such as survival time in NHs and
age, cognitive or functional performance, or number of
concomitant medications.
General linear models
The multivariate approach of general linear models was
used in this study because of the large sample of deceased
participants for whom dates of NHP were available; thus,
no patients were censored. General linear models were
used (1) to simultaneously estimate the possible effect of
the sociodemographic and clinical predictors mentioned
below on the dependent variable “survival time in NHs”
(in years) and (2) to explore the effect of the use of
community-based services on time spent in NHs by adding
those factors to the first model. Nonsignificant variables
(P > 0.05) were eliminated using the backward stepwise
approach. The hierarchical principle was observed in these
analyses; terms that appeared in interactions were not con-
sidered for elimination.
Well-known risk factors, e.g., sex, age at NHP, the
clinician’s estimation of duration of AD, years of educa-
tion, number of apolipoprotein E (APOE) ε4 alleles, and
solitary living at NHP (no/yes), were included in the first
general linear model. Measures of AD severity and pro-
gression, i.e., cognitive (MMSE score only because of its
strong linear correlation with the ADAS-cog), instru-
mental, and basic ADL abilities at NHP and their rates
of change/year before NHP, were also included as inde-
pendent variables. Comorbidity was investigated using
the number of concomitant medications at baseline as a
potential predictor, as well as the presence of specific
medications (no/yes for each group): antihypertensive/
cardiac therapy, antidiabetic drugs, asthma medication,
thyroid therapy, lipid-lowering agents, estrogens, nonste-
roidal anti-inflammatory drugs (NSAIDs)/acetylsalicylic
Wattmo et al. BMC Neurology  (2016) 16:156 Page 3 of 11
acid, antidepressants, antipsychotics, and anxiolytics/seda-
tives/hypnotics. The impact of ChEI therapy during the
SATS was analyzed by including the different drug agents
(coded as dummy variables), ChEI dose, and treatment
duration (in months) in the model. A second general
linear model, together with the abovementioned variables,
included the use of home-help services (h/week) and adult
day care (days/week) at NHP and annual changes in the
volume of these services before NHP.
The change in score (MMSE, IADL, and PSMS) or in
the amount of services/week from baseline to the indivi-
dual’s last evaluation before NHP was divided by the
number of months between these evaluations and multi-
plied by 12. To facilitate comparisons between the MMSE,
IADL, and PSMS scales, changes in the scores reflected as
positive values should be interpreted as indicating impro-
vement and those reflected as negative values as indicating
worsening. Most participants did not receive community-
based services at baseline; therefore, these possible predic-
tors were treated as categorical variables because of their
skewed distributions.
The ChEI dose could vary during the treatment period
for an individual patient and between patients. Therefore,
the mean dose used during the entire follow-up period
was calculated for each individual. Furthermore, to obtain
a similar metric of maximum dosage percentage for the
three ChEI agents, the mean dose was divided by the
maximum recommended dose for each drug agent; i.e.,
10 mg for donepezil, 12 mg for rivastigmine (oral therapy),
and 24 mg for galantamine.
Results
Survival time in nursing homes
The sociodemographic and clinical characteristics of the
220 SATS participants at the start of ChEI treatment
(baseline) and at NHP are shown in Table 1. Overall, their
survival time in NHs was (mean (95 % confidence interval
(CI)) 4.06 (3.69–4.43) years. Females with AD spent a
longer time in NHs than did males, 4.53 (4.09–4.96) years
vs 2.78 (2.19–3.38) years (t218 = −4.71, P < 0.001). Patients
living alone at NHP demonstrated a trend toward a signi-
ficantly longer survival time in NHs vs those living with
family, 4.35 (3.87–4.83) years vs 3.67 (3.10–4.25) years
(t218 = −1.79, P = 0.075). The potential interaction effect
of sex by living status was also analyzed. Post hoc tests
(Bonferroni) showed that males living with a family mem-
ber at NHP, n = 39, spent a shorter time in NHs, on average
(2.15 (1.48–2.83) years) than did patients in the other
groups: females living with family, n = 55, 4.75 (4.00–5.50)
years; males living alone, n = 20, 4.00 (2.96–5.05) years;
and females living alone, n = 106, 4.41 (3.87–4.95) years,
F3,216 = 8.66, P < 0.001. Women living with a family mem-
ber had a lower mean MMSE score at NHP vs females who
lived alone, 15.7 (13.8–17.6) points vs 18.4 (17.5–19.3)
Table 1 Sociodemographic and Clinical Characteristics (n = 220)





Female sex 161/73 % na
APOE genotype, (n = 208) na
No ε4 alleles 57/27 %
One ε4 allele 118/57 %
Two ε4 alleles 33/16 %
Solitary living 116/53 % 126/57 %
Antihypertensive/cardiac therapy 79/36 %
Antidiabetics 9/4 %
Asthma medication 9/4 %
Thyroid therapy 19/9 %
Lipid-lowering agents 15/7 %
Estrogens 17/8 %




Variable Mean ± standard deviation
Estimated age at onset of AD, years 73.5 ± 6.9 na
Estimated duration of AD, years 3.4 ± 2.6 5.1 ± 2.7
Age, years 76.9 ± 5.9 78.6 ± 5.8
Education, years 9.2 ± 2.3 na
MMSE score 20.1 ± 4.0 17.5 ± 5.7
ADAS-cog score (0–70) 24.0 ± 9.7 29.2 ± 12.5
IADL score 18.3 ± 5.1 22.7 ± 4.7












Mean dose of ChEI during
the SATS, mg
Donepezil (n = 138) 6.8 ± 1.8 na
Rivastigmine (n = 37) 5.7 ± 1.9 na
Galantamine (n = 45) 15.1 ± 3.2 na
Time to nursing home placement
from the start of ChEI therapy,
months
19.5 ± 10.0 na
Age at death, years 82.6 ± 6.0 na
AD Alzheimer’s disease, ADAS-cog Alzheimer’s Disease Assessment Scale –
cognitive subscale, APOE apolipoprotein E, ChEI cholinesterase inhibitor,
IADL Instrumental Activities of Daily Living scale, MMSE Mini-Mental State
Examination, na not applicable, NSAIDs nonsteroidal anti-inflammatory
drugs, PSMS Physical Self-Maintenance Scale, SATS Swedish Alzheimer
Treatment Study
aConcomitant medications were not recorded at the postbaseline visits
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points; however, their cognitive status did not differ from
that of the other two groups: males living with family, 16.8
(14.9–18.7) points and males living alone, 19.4 (16.9–21.8)
points, F3,216 = 3.70, P = 0.013. The solitary-living indivi-
duals exhibited a better mean IADL score at NHP, regard-
less of sex: males, 21.5 (19.3–23.7) points and females, 21.5
(20.5–22.4) points vs those living with family: males, 24.6
(23.3–25.8) points and females, 24.2 (23.0–25.4) points,
F3,216 = 7.26, P < 0.001. No significant differences regarding
age or basic ADL at NHP, or number of concomitant medi-
cations at baseline were found among the four groups.
Figure 1 a–b illustrates the patients’ age at onset of AD, age
at baseline (shortly after AD diagnosis), age at NHP, and
age at death, on average, overall, and according to sex, as
well as the interaction effect of sex by living status.
The mean survival time in NHs was shorter for individ-
uals treated with antihypertensive/cardiac therapy at base-
line, 3.39 (2.78–3.99) years vs 4.44 (3.98–4.89) years,
t218 = 2.74, P = 0.007, and for those using anxiolytics/seda-
tives/hypnotics, 3.22 (2.45–4.00) years vs 4.25 (3.84–4.67)
years, t218 = 2.16, P = 0.032. There was a trend toward
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Fig. 1 Time course of events in the SATS according to sociodemographic characteristics. Mean age at AD onset, illness duration, time from diagnosis
(start of cholinesterase inhibitor treatment) to NHP, and survival time in NHs. a. In total and according to sex. Females with AD spent on average 1.75
more years (21 months) in NHs than did males (P < 0.001). No sex-based difference was observed regarding age at AD onset, illness duration, age at
diagnosis, time between diagnosis and NHP, age at NHP, and age at death. b. The interaction effect of sex with living status. Females living with family
showed a trend toward a younger age at the onset of AD symptoms than did the other groups (P = 0.074). Solitary living males with AD exhibited a
trend toward a significantly longer illness duration compared with females living alone (P = 0.055). Males living with a family member had longer time
from AD diagnosis to NHP than did solitary living females (P = 0.022). Moreover, males living with family spent a mean of ~2–2.5 years less time in NHs
compared with the other groups (P < 0.001). No significant differences were detected regarding age at diagnosis, age at NHP, and age at death. AD,
Alzheimer’s disease; NH, nursing home; NHP, nursing home placement; SATS, Swedish Alzheimer Treatment Study
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with antidiabetics at the start of ChEI treatment to exhibit
also a shorter time spent in NHs. Users of antihyperten-
sive/cardiac therapy were older, on average: 80.0 (79.0–
81.0) years vs 77.7 (76.7–78.8) years, t218 = −3.09, P =
0.002; and had a somewhat higher MMSE score at NHP,
18.6 (17.5–19.7) points vs 16.9 (15.9–17.9) points, t218 =
−2.17, P = 0.031, but similar functional capacity compared
with the nonusers. Users of anxiolytics/sedatives/hypnotics
were also older at NHP, 80.5 (78.8–82.1) vs 78.1 (77.3–79.0)
years, t218 = −2.39, P = 0.018, but their cognitive and func-
tional performance did not differ from those of the nonu-
sers. Figure 2 a–b illustrates the patients’ age at onset of
AD, at baseline, at NHP, and at death, on average, according
to use of antihypertensive/cardiac therapy and of anxio-
lytics/sedatives/hypnotics.
A shorter survival time in NHs exhibited weak linear
associations with older age at NHP (r = −0.136, P = 0.043),
lower basic ADL at NHP (PSMS score; r = −0.183, P =
0.007), and a higher number of medications at baseline
(r = −0.170, P = 0.011).
Factors that affect survival time in nursing homes
General linear models using the time between NHP and
death as the dependent variable were built to identify the
sociodemographic and clinical factors that influenced the
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Fig. 2 Time course of events in the SATS according to concomitant medications. Mean age at AD onset, illness duration, time from diagnosis
(start of cholinesterase inhibitor treatment) to NHP, and survival time in NHs. a Antihypertensive/cardiac therapy. The participants without
antihypertensive/cardiac therapy were younger at the onset of AD symptoms (P < 0.001), had a longer illness duration (P = 0.004), and were
younger at the time of diagnosis (P = 0.003) and at NHP (P = 0.002) compared with the individuals who received these medications. The survival
time in NHs was, on average, 1 year longer for patients with no antihypertensive/cardiac therapy (P = 0.007). No significant difference was found
regarding time between diagnosis and NHP, and age at death. b Anxiolytics/sedatives/hypnotics. The participants without these medications
were younger at the onset of AD (P = 0.008), at the time of diagnosis (P = 0.011), and younger at NHP (P = 0.018) compared with the individuals
who received anxiolytics/sedatives/hypnotics. The survival time in NHs was a mean of 1 year shorter for users of these medications (P = 0.032).
No significant difference was observed regarding illness duration, time between diagnosis and NHP, and age at death. AD, Alzheimer’s disease;
NH, nursing home; NHP, nursing home placement; SATS, Swedish Alzheimer Treatment Study
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of the variance in the model was moderate (R = 0.458,
R2 = 0.210, P < 0.001). The multivariate model and signifi-
cant predictors are presented in Table 2. A shorter survival
time in NHs was related to use of antihypertensive/cardiac
therapy, use of anxiolytics/sedatives/hypnotics, worse basic
ADL at NHP, and the interaction term male living with
family. Figure 3 shows the mean age at onset of AD, at
baseline, at NHP, and at death in the four groups of pa-
tients, depending on basic ADL at NHP (PSMS score, 6: no
impairment; 7–9, 10–14, and 15–30: severe impairment).
Discussion
In this longitudinal AD study performed in a routine
clinical practice setting, we found that the mean survival
time in NHs was about 4 years. Females spent 1.75 years
(21 months) more in NHs than males. The general linear
model showed that a shorter stay in NHs was indepen-
dently associated with the interaction term male living
with a family member, use of antihypertensive/cardiac
therapy, use of anxiolytics/sedatives/hypnotics, and lower
basic ADL capacity (but not IADL) at NHP. Cognitive
ability did not affect the survival time in NHs. Males living
with family spent ~2–2.5 years less in NHs compared
with the other groups, despite the absence of significant
differences regarding age, disease severity, or number of
concomitant medications. Users of antihypertensive/cardiac
therapy or anxiolytics/sedatives/hypnotics spent 1 year less,
on average, in NHs than nonusers. Impairment in basic
ADL might imply a shorter time spent in NHs of up to
1.5 years, depending on severity. No relationships between
different aspects of ChEI treatment and survival time in
NHs were detected.
The mean time spent in NHs (4.06 years) found in the
present AD study is consistent with the 4.3 years observed
for demented persons reported by the National Board of
Health and Welfare, Sweden [26]. A recent German study
of dementia [27] described a similar survival time in NHs
for females (mean, 52.5 months), and a slightly longer
time for males (37.1 months) vs our SATS (54.4 and
33.4 months, respectively). Two American studies of AD
reported a shorter time spent in NHs by almost 1 year,
median of 33 and 38.57 months, respectively [18, 19],
which might be explained by differences between health
care systems. In most countries of northern Europe, NHP
is predominantly based on the individual’s need for care,
which is almost exclusively publicly funded and covers the
entire population, irrespective of income or insurance
[28]. This was supported by our finding that the level of
education did not affect survival time in NHs. Social-
service systems that ease the family members’ economic
burden of care can lead to a longer time spent in NHs.
Here, males living with a family member spent a shorter
time (by ~2–2.5 years) in NHs than did the other parti-
cipants, after controlling for sex, age, disease severity, and
concomitant medications; hence, the usually shorter life-
span of males cannot explain this observation. A large
number of previous studies of dementia investigated sep-
arately the potential effects of sex and living status on
community-based service utilization; in contrast, analyses
of the interaction term are scarce. We reported previously
a longer time (mean of 6 months) to use of home-help
services [14] and a lower risk of NHP [16] among male AD
patients living with family vs the corresponding females.
These differences are probably explained by the informal
care provided by female spouses, who are more likely to
provide care for a longer period than male caregivers [29].
Moreover, the service providers may be less alert to the
needs of female caregivers regarding formal help because
they assume that these mostly older women can manage
the care by themselves [30]. Younger females may be more
educated, less committed to caring for relatives, and more
assertive; thus, the demand for formal care and NHs may
increase in the future.
Users of antihypertensive/cardiac therapy or anxiolytics/
sedatives/hypnotics exhibited a shorter life expectancy (by
about 1 year) in our multivariate models. Cardiovascular
disorders are well-known risk factors for increased morta-
lity in NH residents with dementia [20, 31]. The SATS
patients who used antihypertensive/cardiac therapy were
older and cognitively better at NHP, which might explain
the similar age at death compared with nonusers.
Table 2 Factors that Affected the AD patients’ Survival Time in
Nursing Homes, years (Final General Linear Model)
Significant predictorsa β 95 % CI P value
Intercept 2.069 0.521, 3.618 0.009
Sex by living statusb
Females living with family 2.489 1.427, 3.551 <0.001
Females living alone 2.185 1.239, 3.130 <0.001
Males living alone 1.590 0.208, 2.972 0.024
Antihypertensive/cardiac therapy
(no = 0, yes = 1)
−0.884 −1.599, −0.170 0.016
Anxiolytics/sedatives/hypnotics
(no = 0, yes = 1)
−1.030 −1.908, −0.153 0.022
PSMS score at NHP −0.119 −0.208, −0.030 0.009
β values were unstandardized and are expressed per 1 unit increase for
continuous variables, and for the condition present for dichotomous variables
Apolipoprotein E genotype, duration of AD, age at NHP, years of education,
cognitive or instrumental ADL abilities at NHP, cholinesterase inhibitor agent,
dose or duration of treatment, other concomitant medications (antidiabetics,
asthma medication, thyroid therapy, lipid-lowering agents, estrogens, nonsteroidal
anti-inflammatory drugs/acetylsalicylic acid, antidepressants, or antipsychotics),
the amount of home-help services, or adult day care at NHP or the annual
mean changes in these services before NHP were not significant. There were no
associations observed between survival time in nursing homes and the level of
cognitive or functional response to cholinesterase inhibitors after 6 months of
treatment, or rate of disease progression before NHP
AD Alzheimer’s disease, CI confidence interval, NHP nursing home placement,
PSMS Physical Self-Maintenance Scale
aDegree of explained variance, R = 0.458, R2 = 0.210, P < 0.001
bMales living with family were the reference category
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Furthermore, the MMSE scale was not adapted to meas-
ure altered executive function and mental speed, which are
usually related to vascular pathology and might be expected
in users of antihypertensive/cardiac therapy. Tests that
evaluate these abilities specifically might have shown a
greater cognitive impairment. Users of anxiolytics/seda-
tives/hypnotics were also older at NHP and had a similar
age at death as the nonusers. A study of NH residents with
dementia showed that the use of anxiolytics had a positive
effect on basic ADL [32], which might postpone NHP.
Recently, we found an association between the use of an-
xiolytics/sedatives/hypnotics and a longer survival time
[17]. Improved sleep may lead to a more favorable outcome
in AD [33] and might be an additional reason for delayed
NHP.
Cognitive ability at NHP or its rate of progression did
not influence survival time in NHs in the current study,
which is in accordance with most previous studies of
mortality in NH residents with dementia [20, 34], but not
with all [35]. Consistently, cognition was not an important
predictor of use of home-help services [14, 36] or time to
NHP [16, 37]. Rather, a lower cognitive status was associ-
ated with fewer hours of home help [14]. This noteworthy
observation suggests that the individuals’ cognitive ability
was not considered when deciding the amount or level of
community-based care needed, and that the recipients
and family members might have been unable/unwilling to
request additional help. The services provided must be
better tailored to the requirements of persons with cogni-
tive impairment.
In contrast, basic ADL (but not IADL) were an independ-
ent predictor of survival time in NHs in the present study.
Worse basic ADL at NHP, a longer time between AD
diagnosis and NHP, and, thus, a shorter time spent in NHs
exhibited significant relationships, indicating that a longer
period of care in the recipient’s home might reduce survival
time in NHs. However, the burden of care for demented
individuals with loss of many basic ADL must also be
considered; this issue was not addressed in the SATS. Func-
tional disability has been reported as an important pre-
dictor of mortality in many studies of NH residents with
dementia [20, 34]. The time to NHP seems to be more
dependent on the participants’ total ADL or IADL capacity
and their rates of decline [16, 37], whereas basic ADL
deficits affect life expectancy. Progression in IADL might
have a lesser effect on survival vs the consequences of the
loss of crucial functions during the later stages of AD,
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Fig. 3 Time course of events in the SATS according to the basic ADL capacity at NHP. Mean age at AD onset, illness duration, time from diagnosis
(start of cholinesterase inhibitor treatment) to NHP, and survival time in NHs, in the four groups of participants (PSMS score: 6, 7–9, 10–14, and 15–30).
The individuals who exhibited a PSMS score of 10–14 at NHP spent about 0.5 year shorter time in NHs and those who had a PSMS score of ≥15 at
NHP spent an average of ~1.5 years shorter time in NHs compared with patients who had a PSMS score of 6 (no impairment) at NHP (P = 0.045). More
impaired basic ADL at NHP and longer time between diagnosis and NHP showed a significant relationship (P = 0.048). No differences were found
regarding age at AD onset, illness duration, age at diagnosis, age at NHP, and age at death among the four groups. AD, Alzheimer’s disease; ADL,
activities of daily living; NH, nursing home; NHP, nursing home placement; PSMS, Physical Self-Maintenance Scale; SATS, Swedish Alzheimer
Treatment Study
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incontinence, and falls [38]. Therefore, basic ADL might
serve as an indicator of the remaining life-span in end-stage
dementia.
Age was not a significant predictor of survival time in
NHs in our multivariate models, suggesting that the
remaining factors had a stronger effect. Furthermore, the
amount of home-help services or adult day care at NHP,
or the annual change in these services did not predict time
spent in NHs. This indicates that community-based ser-
vices cannot reduce the AD patients’ survival time in NHs
and supports our finding that cognitive status was not
related to service utilization. Home-help services cannot
sufficiently address the needs associated with cognitive
impairment, such as supervision, management of beha-
vioral symptoms, and avoidance of dangerous situations
[36]. A study of adult day-care services observed that the
recipients who used more care/week had an increased risk
of NHP, even after controlling for disease severity and
caregiver burden, which implies that adult day care serves
more as a transitional period to NHP than as a respite,
and, thus, indicates shortened time to admission [39]. This
information is essential for service providers and raises
questions regarding the utility of the services available
currently to community-dwelling people with dementia.
Here, different aspects of ChEI therapy, such as drug
agent, dose, level of short-term response, or treatment
duration, did not affect the survival time in NHs. A
modest-sized mean improvement in cognitive ability for
about 6–12 months [11, 40] and a corresponding reduced
decline in ADL [41] after the initiation of ChEI therapy
were described by previous AD studies. Moreover, higher
ChEI doses have been associated with better longitudinal
cognitive and functional outcomes [11, 13, 42], a lower
volume of community-based care [14], delayed time to
NHP [15, 16], and a longer life-span [17]. Taken together,
the initial response to ChEI, the slowing of disease progres-
sion, and the postponement of the need for community-
based services entail a 6–12 month positive shift in the
disease. Hence, the unchanged length of stay in NHs
observed indicates that this potential increase in life expec-
tancy occurs in the mild-to-moderate stage of AD, when
the persons are able to live in their homes.
The strengths of the SATS are its 6-month, prospective,
well-organized evaluations of cognitive and functional
performance and resource utilization (which is less com-
monly measured in most studies) after the onset of ChEI
treatment. Survival time in this large cohort of “real-life”
AD patients with comorbidities and concomitant medica-
tions from Swedish memory clinics has now been followed
for 17 years. The community-based services in Sweden
are publicly funded and, therefore, accessible to all resi-
dents, regardless of their socioeconomic status [28]. Thus,
we assume that the participants were representative of the
general population and that their needs for formal care
reflected their actual disabilities. Similar to other long-
term observational studies of AD, the SATS is not placebo
controlled (because of ethical concerns) or randomized
with respect to ChEI agent. Another limitation is that
somatic disorders and other health events, for instance,
were not recorded between the last follow-up and death,
which may have affected mortality.
Very few studies of AD exclusively have investigated
the residents’ length of time spent in NHs and possible
predictors that might affect this parameter, probably
because of the long study time that would be required.
No previous studies addressed the associations between
type of ChEI agent, dose and duration of ChEI therapy,
and survival time in NHs; thus, additional studies are war-
ranted. The potential effect of sociodemographic factors
and interaction terms—such as living status by sex, as well
as various comorbidities and medications, such as anxio-
lytics/sedatives/hypnotics—on time spent in NHs needs
further investigation.
Conclusions
In conclusion, critical characteristics that may influence
the survival time in NHs (mean, ~4 years) were identified
in this naturalistic AD study. A significant interaction effect
showed that men living with a family member spent less
time in NHs (by ~2–2.5 years) compared with the other
patients, after controlling for several factors. The possible
caregiver burden on female spouses who care for husbands
with AD over several years needs attention, and probably
support and respite. Worse basic ADL at NHP, but not
cognitive status, were related to a shorter stay in NHs,
which might mirror the magnitude of the loss of essential
functions during the later AD stages and the fact that the
individual’s cognitive ability was less considered at NHP.
The amount of, and changes in, community-based services
did not affect survival time in NHs, which indicates that
these types of care are not sufficient to postpone NHP. No
relationships between different aspects of ChEI treatment
and time spent in NHs were detected; therefore, we
suggest that the positive effects of ChEIs do not prolong
the end-stage of AD or the survival time in NHs.
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